Exodus Point Capital Management, LP Lyell Immunopharma, Inc. Transaction History

Exodus Point Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.71 - $3.07 $419,091 - $752,404	245,083 New	245,083 $547,000
Q1 2022 May 13, 2022	SELL	$5.05 - $7.7 $78,275 - $119,350	-15,500 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$7.13 - $15.19 $110,515 - $235,445	15,500 New	15,500 $120,000
Q3 2021 Nov 15, 2021	SELL	$11.0 - $17.95 $227,667 - $371,511	-20,697 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$15.99 - $16.89 $330,945 - $349,572	20,697 New	20,697 $336,000

118

144M

2.6K

7.5K

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $300M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.